Detalhe da pesquisa
1.
[A Case of Chromophobe Renal Cell Carcinoma Producing Interleukin-6 with Stauffer Syndrome].
Hinyokika Kiyo
; 69(8): 215-220, 2023 Aug.
Artigo
em Japonês
| MEDLINE | ID: mdl-37667598
2.
Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis.
BJU Int
; 130(2): 226-234, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34110696
3.
Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
Int J Urol
; 29(5): 398-405, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35080069
4.
Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
Cancer Sci
; 112(2): 760-773, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33283385
5.
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Cancer Sci
; 112(9): 3616-3626, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34145921
6.
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Cancer Sci
; 112(4): 1524-1533, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33159829
7.
Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy.
Int J Clin Oncol
; 26(11): 2104-2112, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34313904
8.
Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma.
Cancer Sci
; 111(7): 2460-2471, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32402135
9.
Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.
J Urol
; 199(4): 933-939, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29037861
10.
Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guérin after radical nephroureterectomy for upper urinary tract urothelial carcinoma.
BJU Int
; 121(5): 764-773, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29281857
11.
Correction: CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.
BMC Cancer
; 22(1): 813, 2022 Jul 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35879687
12.
[Laparoscopic Pyelolithotomy in a Horseshoe Kidney : A Case Report and Review of the Literature].
Hinyokika Kiyo
; 63(4): 157-161, 2017 Apr.
Artigo
em Japonês
| MEDLINE | ID: mdl-28506053
13.
IV Immunoglobulin for Acute Lung Injury and Bacteremia in Pseudomonas aeruginosa Pneumonia.
Crit Care Med
; 44(1): e12-24, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26317571
14.
Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
Microbiol Immunol
; 60(2): 114-20, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26696420
15.
Changes in oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma treated in the last two decades: a retrospective analysis based on a multicenter collaborative study.
Jpn J Clin Oncol
; 46(12): 1148-1155, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27576438
16.
CYP1B1 promotes tumorigenesis via altered expression of CDC20 and DAPK1 genes in renal cell carcinoma.
BMC Cancer
; 15: 942, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26626260
17.
V-antigen homologs in pathogenic gram-negative bacteria.
Microbiol Immunol
; 58(5): 267-85, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24641673
18.
Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer.
Hiroshima J Med Sci
; 62(1): 13-9, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23600329
19.
[8. How We Can Treat the Patients with Prostate Cancer-Surgical Option and Change over Time].
Nihon Hoshasen Gijutsu Gakkai Zasshi
; 74(2): 208-218, 2018.
Artigo
em Japonês
| MEDLINE | ID: mdl-29459549
20.
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Anticancer Res
; 43(11): 5041-5050, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37909969